As of 2026-03-20, the Relative Valuation of BioMark Diagnostics Inc (BUX.CN) is (0.01) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.60 CAD, the upside of BioMark Diagnostics Inc based on Relative Valuation is -102.0%.
The range of the Relative Valuation is (0.01) - (0.10) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.6x - 6.8x | 0.8x |
| Forward P/E multiples | 0.6x - 6.3x | 0.7x |
| Fair Price | (0.01) - (0.10) | (0.01) |
| Upside | -101.7% - -117.2% | -102.0% |
| Date | P/E |
| 2026-03-17 | -37.27 |
| 2026-03-16 | -36.66 |
| 2026-03-13 | -37.88 |
| 2026-03-11 | -37.88 |
| 2026-03-10 | -37.88 |
| 2026-03-09 | -36.66 |
| 2026-03-06 | -37.27 |
| 2026-03-05 | -37.27 |
| 2026-03-04 | -37.88 |
| 2026-03-03 | -39.10 |
| 2026-03-02 | -35.44 |
| 2026-02-27 | -35.44 |
| 2026-02-26 | -33.60 |
| 2026-02-25 | -34.21 |
| 2026-02-24 | -34.83 |
| 2026-02-23 | -34.21 |
| 2026-02-20 | -34.83 |
| 2026-02-19 | -35.44 |
| 2026-02-18 | -32.38 |
| 2026-02-13 | -32.99 |
| 2026-02-11 | -33.60 |
| 2026-02-10 | -30.55 |
| 2026-02-09 | -30.55 |
| 2026-02-06 | -30.55 |
| 2026-02-05 | -29.63 |
| 2026-02-03 | -29.94 |
| 2026-02-02 | -29.94 |
| 2026-01-30 | -30.55 |
| 2026-01-29 | -29.63 |
| 2026-01-28 | -29.33 |
| 2026-01-27 | -30.55 |
| 2026-01-26 | -30.55 |
| 2026-01-23 | -32.99 |
| 2026-01-22 | -29.94 |
| 2026-01-21 | -30.55 |
| 2026-01-20 | -27.49 |
| 2026-01-19 | -29.33 |
| 2026-01-16 | -29.94 |
| 2026-01-15 | -29.63 |
| 2026-01-14 | -28.72 |
| 2026-01-13 | -29.33 |
| 2026-01-12 | -29.33 |
| 2026-01-05 | -29.33 |
| 2026-01-02 | -27.80 |
| 2025-12-30 | -28.72 |
| 2025-12-29 | -28.11 |
| 2025-12-24 | -29.33 |
| 2025-12-23 | -29.33 |
| 2025-12-22 | -28.11 |
| 2025-12-19 | -26.88 |